Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial
Phase II trial shows azacitidine and luspatercept improve quality of life in myelodysplastic syndrome, indicating safety and efficacy for high-risk patients.
Key Points
To evaluate the safety, tolerability, and efficacy of metronomic azacitidine with luspatercept in patients with intermediate- to high-risk myelodysplastic syndrome.
Conducted a prospective, single-center, single-arm phase II clinical trial.
Enrolled adult patients with intermediate- to high-risk myelodysplastic syndrome.
Administered azacitidine subcutaneously twice weekly and luspatercept weekly; assessed responses with modified IWG criteria.
Enrolled 24 patients with a median age of 71 years and a median follow-up of 3 months.
67% overall response rate and 21% complete remission rate observed.
32% of transfusion-dependent patients achieved transfusion independence.